此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer

2026年9月30日 更新者:Shafia Rahman、Ohio State University Comprehensive Cancer Center

DCE-MRI-Informed Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer

This clinical trial tests how well dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) with standard clinical evaluation works to assess treatment response for patients with pancreatic cancer that may be able to be removed by surgery (borderline resectable). Borderline resectable pancreatic cancer (BRPC) is a certain type of pancreatic cancer that involves the arteries or veins near the pancreas. With the right treatment before surgery, it can be removed (resected) successfully. An MRI (magnetic resonance imaging) scan creates clear images of the structures inside the body using a large magnet, radio waves, and a computer. DCE-MRI can be used to calculate the blood perfusion. Blood perfusion can show disease status. Using DCE-MRI as part of standard clinical evaluation may provide a more accurate treatment response assessment for patients with BRPC.

研究概览

详细说明

PRIMARY OBJECTIVE:

I. To evaluate the association between the availability of DCE-MRI-derived information and R0 resection rates in patients with BRPC, compared to standard-of-care management.

SECONDARY OBJECTIVE:

I. To assess the association between DCE-MRI parameters and tumor microenvironment features measured by digital histopathology.

OUTLINE:

Within two weeks prior to therapy initiation, patients receive gadolinium based contrast intravenously (IV) and undergo DCE-MRI. Patients then undergo standard of care treatment with gemcitabine and nab paclitaxel or fluorouracil, oxaliplatin, irinotecan and leucovorin, per the treating gastroenterology oncologist. Approximately 6 weeks after therapy initiation and again within 1 week prior to surgery, patients receive gadolinium based contrast IV and undergo DCE-MRI again. Patients undergo computed tomography (CT) scan and blood sample collection throughout the study.

研究类型

介入性

注册 (估计的)

50

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Ohio
      • Columbus、Ohio、美国、43210
        • 招聘中
        • Ohio State University Comprehensive Cancer Center
        • 接触:
        • 首席研究员:
          • Shafia Rahman, MD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization for release of personal health information

  • Age ≥ 18 years at the time of consent

  • Patients have Eastern Cooperative Group (ECOG) performance status of 0-2

  • Histological or cytological evidence of pancreatic adenocarcinoma

  • Patients must have borderline resectable primary tumor per National Comprehensive Cancer Network (NCCN) definitions version 2.2025 based on contrast-enhanced CT or MRI (CT or MRI without contrast as part of positron emission tomography [PET]/CT or PET/MRI is NOT acceptable; CT or MRI with contrast as part of PET/CT or PET/MRI is acceptable) of the chest, abdomen, and pelvis, where borderline resectable is defined as all of the following:

    • Solid tumor involvement of ≤ 180° with the celiac artery, common hepatic artery, and superior mesenteric artery (and, if present, replaced right hepatic artery).
    • Solid tumor involvement of > 180° with the portal vein and/or superior mesenteric vein, and a patent portal vein/splenic vein confluence.
    • Solid tumor contact with the inferior vena cava.
    • Absence of metastatic disease
  • Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1 for solid tumors within 28 days prior to registration

  • Patients must not have received prior surgery, radiation therapy, chemotherapy, targeted therapy, or any investigational therapy for pancreatic cancer

  • Absolute neutrophil count (ANC) ≥ 1.5×109/L (obtained within 28 days prior to registration)

  • Platelet count ≥ 100,000/mm3 (100 × 109/L) (obtained within 28 days prior to registration)

  • Hemoglobin (Hgb) ≥ 8 g/dL (obtained within 28 days prior to registration)

  • Aspartate transaminase (AST), serum glutamic-oxaloacetic transaminase (SGOT), alanine transaminase (ALT), serum glutamic-pyruvic transaminase (SGPT) ≤ 3 × upper limit of normal range (ULN) (obtained within 28 days prior to registration)

  • Total bilirubin ≤ 2 × ULN (obtained within 28 days prior to registration)

  • Females of childbearing potential must have a negative pregnancy test (serum or urine) within 3 days prior to registration

  • Females of childbearing potential must be willing to abstain from vaginal intercourse or use an effective method(s) of contraception from the time of informed consent, during the study, and for 6 months after the last dose of study drug(s). Males must be willing to abstain from vaginal intercourse or to use an effective method(s) of contraception from initiation of treatment, during the study, and for 3 months after the last dose of study drug(s)

  • As determined by the enrolling physician or protocol designee, the ability of the subject to understand and comply with study procedures for the entire length of the study

  • History of HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months of registration are eligible for this trial

  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated. Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, the HCV viral load must be undetectable to be eligible for this trial

  • Co-enrollment on a non-interventional therapeutic trial is allowed. This includes observational trials and biomarker collection trials

Exclusion Criteria:

  • Evidence of distant metastasis

  • History of significant uncontrolled cardiovascular disease. Significant cardiac disease includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension; congestive heart failure of the New York Heart Association (NYHA) Class II or worse (slight limitation of physical activity; comfortable at rest, but ordinary activity results in fatigue, palpitation, or dyspnea)

  • History of arrhythmia that is symptomatic or requires treatment. However, patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial

  • Patient with a history of allergy or hypersensitivity to any of the study drugs or any of their excipients

  • Pregnant or lactating

    • NOTE: breast milk cannot be stored for future use while the mother is being treated in this study
  • Patient with any other concurrent severe and/or uncontrolled medical condition that would, in the investigators' judgment, cause unacceptable safety risks, contraindicate patient participation in the clinical study, or compromise compliance with the protocol (e.g., chronic active hepatitis, active untreated or uncontrolled fungal, bacterial, or viral infections, etc.)

  • No prior malignancy is allowed except for adequately treated basal (or squamous cell) skin cancer, in situ cervical cancer, or other cancer for which the patient has been disease-free and treatment-free for at least two years

  • Patient who is unwilling or unable to comply with study procedures

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Diagnostic (DCE-MRI)

Within two weeks prior to therapy initiation, patients receive gadolinium based contrast IV and undergo DCE-MRI. Patients then undergo standard of care treatment with gemcitabine and nab paclitaxel or fluorouracil, oxaliplatin, irinotecan and leucovorin, per the treating gastroenterology oncologist. Approximately 6 weeks after therapy initiation and again within 1 week prior to surgery, patients receive gadolinium based contrast IV and undergo DCE-MRI again. Patients undergo CT scan and blood sample collection throughout the study.

Undergo blood sample collection

其他名称:
  • 生物样本采集
  • 收集的生物样本
  • 标本采集
  • 样本收集

Undergo CT scan

其他名称:
  • CT
  • 猫
  • 电脑扫描
  • 计算机轴向断层扫描
  • 计算机断层扫描
  • CT扫描
  • 断层扫描
  • 计算机轴向断层扫描(程序)
  • 计算机断层扫描 (CT) 扫描
  • 诊断猫扫描
  • 诊断猫扫描服务类型

Undergo DCE-MRI

其他名称:
  • 磁共振成像
  • 大肠磁共振成像
  • 动态对比增强 MRI
  • 大商所

Given fluorouracil

其他名称:
  • 5-氟嘧啶
  • 氟嘧啶
  • 5氟尿嘧啶
  • 5 氟尿嘧啶
  • 5傅
  • 5-Fluoro-2,4(1H, 3H)-pyrimidinedione
  • 5-氟尿嘧啶
  • 5福
  • 5FU
  • 精确站点
  • 卡拉克
  • 氟尿嘧啶
  • 氟黄素
  • 氟里尔
  • 氟芽素
  • 氟核糖
  • 罗 2-9757
  • Ro-2-9757

Given IV

其他名称:
  • 钆配合物
  • 钆基造影剂
  • 钆螯合剂

Given gemcitabine

其他名称:
  • dFdCyd
  • dFdC
  • 二氟脱氧胞苷

Given irinotecan

Undergo leucovorin

其他名称:
  • 维考林
  • 亚叶酸
  • 阿地那巴
  • 钙化叶素
  • 钙 (6S)-亚叶酸
  • 亚叶酸钙
  • 卡尔福莱克斯
  • 卡利纳特
  • 头孢叶林
  • 胆磷脂
  • 雪铁龙
  • 柠檬酸因子
  • Cromatonbic 福利尼科
  • 达利醇
  • 消毒剂
  • 潜水艇
  • Ecofol
  • 埃莫维斯
  • 因子,柠檬酸
  • 弗林肯A
  • 佛拉伦
  • 叶黄素
  • FOLI细胞
  • 福利本
  • 福立丹
  • 立达
  • 福利纳克
  • 叶酸钙
  • 亚叶酸钙盐五水合物
  • 叶绿素
  • 福林维特
  • 福利普斯
  • 福利克斯
  • 伊莫
  • Lederfolat
  • 莱德福林
  • 白细胞
  • 苏叶灵
  • Rescuvolin
  • 托诺福林

Given nab-paclitaxel

其他名称:
  • ABI-007
  • Abraxane
  • 白蛋白结合型紫杉醇
  • 阿比007
  • 白蛋白稳定的纳米粒子紫杉醇
  • 纳米颗粒白蛋白结合紫杉醇
  • 纳米紫杉醇
  • 紫杉醇白蛋白
  • 紫杉醇白蛋白稳定的纳米颗粒制剂
  • 蛋白结合型紫杉醇
  • ABI007
  • 紫杉醇蛋白结合
  • 紫杉醇纳米颗粒白蛋白结合
  • 纳韦鲁克利夫

Given oxaliplatin

其他名称:
  • 1-OHP
  • 大古丁
  • 达克普拉
  • 依洛沙丁
  • 艾恒
  • 爱恒
  • 二氨基环己烷草酸铂
  • 依洛沙汀
  • JM-83
  • 草酸铂
  • 零售价 54780
  • RP-54780
  • SR-96669
  • SR96669
  • 埃尔普拉特
  • 杰米83
  • JM83
  • RP54780
  • SR 96669

The Point-of-care Portable Perfusion Phantom (P4) is a small, non-invasive calibration device developed to support quality assurance of quantitative magnetic resonance imaging (MRI). The device is designed to reproduce controlled imaging properties comparable to those observed in human tissue, allowing assessment of scanner performance during image acquisition.

其他名称:
  • Phantom P4 calibration device

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
R0 resection rate
大体时间:At time of surgery

Will be calculated as the proportion of patients achieving R0 resection among evaluable participants, along with a 90% confidence interval based on the binomial distribution. Comparisons of R0 resection rates between the prospective cohort and the matched control group will be conducted using Fisher's exact test.

At time of surgery

次要结果测量

结果测量
措施说明
大体时间
Dynamic contrast enhanced magnetic resonance imaging parameters
大体时间:At time of surgery

Will be compared with histopathologic findings in resected tumors. Associations between imaging parameters and tumor regression scores will be evaluated using graphical methods and Spearman correlation analysis.

At time of surgery

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Shafia Rahman, MD、Ohio State University Comprehensive Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

有用的网址

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年10月1日

初级完成 (估计的)

2027年12月31日

研究完成 (估计的)

2027年12月31日

研究注册日期

首次提交

2026年7月10日

首先提交符合 QC 标准的

2026年7月10日

首次发布 (实际的)

2026年7月15日

研究记录更新

最后更新发布 (实际的)

2026年10月5日

上次提交的符合 QC 标准的更新

2026年9月30日

最后验证

2026年9月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅